NATO Innovation and Earlybird led a $35m Series A round in Portal Biotech.

NATO Innovation and Earlybird, a venture capital firms, led a $35m Series A round in Portal Biotech, a biotechnology company, with participation from SCVC, Pillar VC, 8VC, Amino Collective, Outsized, We Venture Capital, British Business Bank, and WS Investment Company. "Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level—on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing," Andy Heron, Portal Biotech Co-Founder and CEO.